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Background: Approximately 100,000 persons with sickle cell disease (SCD) live in the United States, including
15,000 in the Midwest. Unfortunately, many patients experience poor health outcomes due to limited access
to primary care providers (PCPs) who are prepared to deliver evidence-based SCD care. Sickle Treatment and
Outcomes Research in the Midwest (STORM) is a regional network established to improve care and
outcomes for individuals with SCD living in Indiana, Illinois, Michigan, Minnesota, Ohio, and Wisconsin.
Methods: STORM investigators hypothesized that Project ECHO† methodology could be replicated to create
a low-cost, high-impact intervention to train PCPs in evidence-based care for pediatric and young adult
patients with SCD in the Midwest, called STORM TeleECHO. This approach utilizes video technology for
monthly telementoring clinics consisting of didactic and case-based presentations focused on the National
Heart, Lung and Blood Institute (NHLBI) evidence-based guidelines for SCD.
Results: Network leads in each of the STORM states assisted with developing the curriculum and are
recruiting providers for monthly clinics. To assess STORM TeleECHO feasibility and acceptability, monthly
attendance and satisfaction data are collected. Changes in self-reported knowledge, comfort, and practice
patterns will be compared with pre-participation, and 6 and 12 months after participation.
Conclusions: STORM TeleECHO has the potential to increase implementation of the NHLBI evidence-based
guidelines, especially increased use of hydroxyurea, resulting in improvements in the quality of care and
outcomes for children and young adults with SCD. This model could be replicated in other pediatric chronic
illness conditions to improve PCP knowledge and confidence in delivering evidence-based care.
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ickle cell disease (SCD) is a group of disorders, in
which red blood cells change to a ‘sickled’ crescent
shape, which leads to a myriad of acute and chronic
clinical complications. SCD affects millions of people
around the globe, and is frequently found among persons
living in North and South America, the Caribbean and
Central America, India, Saudi Arabia, and Mediterranean
countries (Turkey, Greece, and Italy) (1).

S

SCD is among the most common disorders identified
via universal newborn screening in the United States,
with an incidence higher than that for all other genetic
conditions including congenital hypothyroidism and
cystic fibrosis (25). There are approximately 100,000
patients living with SCD in the United States (6),
including an estimated 15,000 patients located in the
Midwest (7).
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SCD was once primarily a childhood disease, since
many patients died before adulthood; today over 95% of
children diagnosed at birth survive to young adulthood
but still suffer early mortality by age 40 years (8, 9).
This shift in mortality from childhood to adulthood has
been accompanied by an increase in serious morbidity
from chronic organ damage among teens and young
adults including cerebrovascular, cardiopulmonary, and
renal disease, all of which are major contributors to early
death (10, 11). Severe pain is the most common cause for
hospitalization and acute morbidity, and requires extensive pain management that patients receive from various
clinical settings, including Emergency Departments and
primary care providers (PCPs) (12).
In late 2014, the National Heart, Lung and Blood
Institute (NHLBI) of the National Institutes of Health
published evidence-based guidelines for the management
of pediatric and adult SCD, including recommendations
for increasing hydroxyurea use in all age groups (13).
Hydroxyurea is a daily oral medication that can change
the clinical course of SCD, with significant reduction in
the frequency of hospitalizations, transfusions, pain, and
other complications, (1416) and increased survival for
both pediatric and adult patients (1720). Despite these
known clinical benefits, only 2030% of eligible adults in
the United States are prescribed the medication (21, 22).
Provider knowledge and comfort level with hydroxyurea
is one of the barriers that have limited access to and use
of the therapy by patients (23). Many provider concerns
about long-term side effects are based solely on theoretical risks; for example, studies have shown that 27%
of pediatric providers (24) and 40% of adult providers
(25) fear that patients could develop cancer from taking
hydroxyurea, despite the substantial clinical experience to
date that does not support those concerns (26, 27).
Complex chronic diseases such as SCD can be difficult
to manage, especially for PCPs with limited experience,
ancillary support, and time to manage SCD-related pain
and complications (28). While specialists exist for pediatric care, there is a paucity of hematologists specializing
in SCD for adults, which makes accessibility to PCPs
knowledgeable about SCD vital. Unfortunately, there are
few PCPs who are well-informed about the guidelines and
confident in delivering evidence-based care to the SCD
population. PCPs and family physicians generally report
a low comfort level with treating patients with SCD, which
is particularly true for providers who see few patients with
SCD in their practice (29).
To increase the knowledge and comfort level of PCP’s
caring for children and adults with SCD in the Midwest,
the Sickle Treatment and Outcomes Research in the
Midwest (STORM) regional network replicated the
†
Project ECHO model. Project ECHO (Extension for
Community Healthcare Outcomes), developed at the
University of New Mexico (UNM) Health Sciences
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Center in 2003 (30), is an innovative approach to building
PCPs’ capacity to treat complex diseases by giving them
specialized knowledge and support (31). The four principles of Project ECHO are 1) using telehealth technology
to build healthcare resources where they are scarce,
2) sharing best practices to reduce variation in clinical
care, 3) utilizing practice-based learning to develop
specialty expertise among providers, and 4) monitoring
and evaluating provider outcomes (32). Project ECHO
was primarily designed for rural outreach to providers,
but several projects have demonstrated their effectiveness
in an urban setting (33).
We hypothesize that Project ECHO could be replicated
to provide specific training for PCPs caring for children
and adults with SCD, and promote effectively prescribing
hydroxyurea, ultimately resulting in improved clinical
care and outcomes. We now describe our methods and
approach for replicating the Project ECHO model, including the outcomes targeted to assess its effectiveness at
increasing PCP knowledge, competence, and confidence,
and ultimately changing practice behaviors in managing
patients with SCD.
This continuing education model documents provider
attendance in the continuing medical education (CME)
intervention and also follows an interactive, expanded
outcomes educational framework with an emphasis on
educational planning and instructional design throughout the activity, to ultimately change provider competence
and performance.

Methods
STORM TeleECHO
STORM is a regional network funded by the Health
Resources and Services Administration (HRSA) as a Sickle
Cell Disease Treatment Demonstration Project. The
grant is based at Cincinnati Children’s Hospital Medical
Center (CCHMC) and covers the states of Indiana, Illinois,
Michigan, Minnesota, Ohio, and Wisconsin. STORM
seeks to increase the number of PCPs knowledgeable about
the overall management and treatment of SCD, and
especially to increase the number prescribing hydroxyurea.
The STORM TeleECHO consists of a ‘hub’ team that
is led by the STORM Regional Coordinating Center,
based at the Cincinnati Comprehensive Sickle Cell Center
within CCHMC. The hub team includes a multidisciplinary clinical expert team, project management support,
and technology support from the Center for TeleHealth.
The STORM TeleECHO hub team was the first to participate in immersion training by the American Academy
of Pediatrics (AAP) Superhub team in December 2015.
The AAP Superhub team serves as a resource center that
provides technical assistance and leverages resources for
the STORM TeleECHO team from planning through
implementation.
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STORM Networks sites (one lead in each state) and
PCP sites (numerous locations in each state) serve as
STORM TeleECHO ‘spokes’. STORM Network sites
began recruiting PCPs in January 2016 via personal and
professional connections, outreach at provider conferences, and mailings and emails to providers. To date,
most spokes have recruited 34 provider groups with a
goal of 1020 per state. Provider groups include at least
one physician, but may include a multidisciplinary team.
Upon registering, providers are required to complete a
baseline assessment about their practice and knowledge,
comfort level, and experience treating patients with SCD,
including hydroxyurea prescribing practices. This formative assessment is important to guide the educational
content of STORM TeleECHO to meet the learners’
needs and education gaps, while aligning the curriculum
with evidence-based care guidelines.
STORM TeleECHO clinic design
The TeleECHO clinic model utilizes telementoring and
state-of-the-art, low-cost technology to link subspecialists
and PCPs. Telementoring is defined as the use of electronic information and telecommunication technologies
to support long-distance professional health-related education (34). TeleECHO clinics can range from 60 to
120 min and include a brief 1520 min didactic followed
by 12 case presentations with facilitated discussion.
STORM TeleECHO didactics topics were selected based
on the NHLBI guidelines (13) and are presented by
nationally recognized pediatric and adult hematologists
with expertise in SCD (Table 1). Providers and other
participants submit cases using a HIPAA-protected,
Table 1. STORM TeleECHO didactic topics
Additional evidence-based
NHLBI guidelines content

content

Acute chest syndrome

Abdominal complaints

Chronic pain

Emergency department use

Hydroxyurea

Health equity

Leg ulcers

Healthy living with SCD

Overview of adult complications Home pain management plan
Overview of pediatric
complications

Neurocognitive complications

Pain management

Newborn screening follow-up

Pediatric infection

Patient experience panel

Priapism

Psychosocial issues

Pulmonary complications

Quality of life

Renal complications

Transition to adult care

Retinopathy

Stroke

Transfusions
NHLBI, National Heart, Lung and Blood Institute; SCD, sickle cell
disease; STORM, Sickle Treatment and Outcomes Research in
the Midwest.

de-identified pediatric or adult case-presentation template that includes relevant medical history, laboratory
results, psychosocial history, and treatment plan to the
‘hub’ prior to clinics. To protect patient confidentiality,
case presenters are instructed to refer to the case ID and
template during their verbal presentations. The goal of
the discussions is to promote learning through a robust
discussion of clinical and psychosocial issues. During the
discussion, all participants are permitted to ask questions
and/or provide treatment recommendations. Audience
participation and interaction is encouraged, and one
strategy for facilitating a robust discussion is integrating
an audience-response system to gauge clinical decisions
during the case discussion. After the clinic, case presenters receive a written summary of the recommendations with the following disclaimer:
based upon general scientific principles, intended
for broad and general physician understanding and
knowledge and is offered solely for educational
purposes, and should in no way constitute a formal
or informal medical consultation.

All treatment decisions are therefore the responsibility
of the presenter, and none of the STORM TeleECHO
partners is liable for any adverse events. Presenters can
then follow up with STORM sites in their respective states
for localized mentoring, consultations, or referrals. Because the purpose of STORM TeleECHO is to improve
the knowledge of regional PCPs, the CCHMC Institutional Review Board deemed it exempted from review and
waived the requirement for written informed consent.
Providers who wish to receive AMA PRA Category 1
CME credits from CCHMC for attending the STORM
TeleECHO clinics must complete a summative evaluation after each session, which includes an assessment to
determine if the learning objectives presented will lead to
the desired outcomes of changed practice behavior.
Technology
STORM TeleECHO participants are encouraged to participate using the Internet and a webcam to create a virtual
learning environment. The Cisco WebExTM technology
platform is used during the clinics. Didactic presentations
are recorded and archived on a password-protected Sharepoint site, along with supplemental educational materials,
that can be accessed by participants after the STORM
TeleECHO clinics as reinforced learning activity tools.

Results
STORM performance
During the first 6 months of STORM TeleECHO,
6 monthly teleclinics have been conducted. There have
been 38 registered participants from 7 states including all
states in the STORM region (see Fig. 1), and 4 observers
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several PCPs/specialists who follow patients with SCD
and have limited access to SCD resources. With an
ongoing networking and a strategic marketing plan to
engage more PCPs to join STORM TeleECHO clinics,
the number of potential patients’ whose care will be
impacted by transformed clinical practice will increase.

Fig. 1. STORM regional network TeleECHO map. Six
states, namely Ohio, Indiana, Illinois, Michigan, Minnesota,
and Wisconsin, are involved in the network.

from federal agencies and professional organizations.
Physicians (64%), nurse practitioners (5%), and other disciplines (31%) have participated in STORM TeleECHO.
There have been an additional 26 participants who have
attended clinics without registering, or registered but
not attended clinics to date. Practice specialties include
pediatric and adult hematology, internal medicine, family
practice, and primary care. Didactic presentations include
an overview of pediatric complications; an overview of
adult complications in SCD; newborn screening for hemoglobin disorders; psychosocial issues in SCD; hydroxyurea;
and abdominal complications. Nearly 100% of participants have reported an increase in knowledge about SCD
management as a result of STORM TeleECHO.
STORM sites and PCP outreach
The geographic setup of the STORM network is illustrated in Fig. 2. All six states in the STORM network
have a single physician champion and have recruited

Feasibility and acceptability
Monthly outcome measures include clinic attendance,
attendee type (PCP, subspecialist, physician assistant,
etc.), satisfaction, and number and type of cases presented.
These data (except for satisfaction) are tracked via a
Project ECHO secure web-based data platform, known as
iECHOTM, which is a Project ECHO network project
management tool that tracks attendance, number and type
of case presentations, and the number of CME credits
awarded to participants. No protected health information
is entered into the database. Clinic evaluations to assess
satisfaction follow standard wording required by the
CCHMC Office of Continuing Medical Education.
Effectiveness and impact
Provider knowledge and self-efficacy of the NHLBI SCD
guidelines and practice patterns will be assessed at baseline, 6 and 12 months after participating in STORM
TeleECHO clinics (Table 2). Evaluations are administered
via a SurveyMonkey web-based survey after each monthly
clinic. Surveys use Likert-scale and open-ended questions
to assess clinical expertise, knowledge of evidence-based
guidelines for SCD, and hydroxyurea prescribing patterns.
Qualitative data on program effectiveness demonstrated
by self-reported practice changes as an objective measure

Fig. 2. STORM regional network TeleECHO map of participants.
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Table 2. STORM TeleECHO provider self-efficacy, benefits, and practice measures
Provider self-efficacy: rate your ability to do each of the following
Provide primary care for pediatric patients with SCD
Provide primary care for adult patients with SCD
Manage acute pain in pediatric patients with SCD
Manage acute pain in adult patients with SCD
Manage chronic pain in pediatric patients with SCD
Manage chronic pain in adult patients with SCD
Identify suitable candidates for disease modifying therapies, such as hydroxyurea
Prescribe disease modifying therapies, such as hydroxyurea
Serve as a provider for SCD patients
Provider benefits: provide your assessment for each of the following
Through the STORM TeleECHO telehealth clinics, I am learning best-practice care for SCD
I learn with guidance from STORM TeleECHO specialists in SCD management, whose knowledge and skills I respect
I am developing my clinical expertise through participation in STORM TeleECHO
My participation in STORM TeleECHO benefits patients under my care
The patients under my care receive best-practice care for SCD
I apply what I have learned about best practices through STORM TeleECHO to all of my patients with SCD
Provider practices: describe the current treatment patterns for your patients
Of the patients you see with SCD, what percentage is eligible for hydroxyurea?
Of the patients eligible, what percentage has been prescribed hydroxyurea?
What percentage of patients is up to date with pneumococcal vaccinations, as documented in the medical record?
What percentage of patients is on chronic transfusions ( 46 transfusions in the past 12 months)?

of impact will also be summarized and used to make
program adaptations.

Discussion
Project ECHO was originally created to increase access to
care for patients with hepatitis C in rural New Mexico
because rural providers were unprepared to treat these
patients. The UNM Health Sciences Center, the primary
subspecialty clinic in the state, sought to reduce wait times
for appointments, decrease travel for patients with hepatitis C, and improve treatment outcomes (35). They also
hoped to build a bridge between rural PCPs and an urban
academic medical center. UNM Project ECHO has since
partnered to replicate the model in an effort to ‘demonopolize’ medical knowledge to improve healthcare in
patients with diabetes, asthma, HIV/AIDS, chronic pain,
pediatric obesity, substance use disorders, cardiovascular
conditions, rheumatoid arthritis, and mental illness. Data
consistently show that through participation in ECHOs,
community-based PCPs are able to provide higher quality
evidence-based chronic disease care and management
(36). An additional benefit has been the creation of
‘communities of practice’, which increases PCP’s satisfaction and reduces isolation and burnout (37).
This is the first report of adapting Project ECHO to
patients with SCD. Our design has replicated the UNM
Project ECHO model using a regional approach to translate the NHLBI’s evidence-based sickle cell management
guidelines to improve the practice of PCPs treating
pediatric and young adult patients with SCD. The Pro-

ject ECHO model allows providers to connect to academic medical centers and specialists in an interactive,
performance-based continuing education forum that
will improve their knowledge and comfort level, and
change practice behaviors (38). In this way, the STORM
TeleECHO project will help to achieve our STORM
network goals of increasing the number of providers
knowledgeable about SCD, and increasing the number of
providers prescribing hydroxyurea. The data on attendance, participation (e.g., submitting cases), and overall
satisfaction will provide information about the feasibility
of this method for increasing provider self-efficacy in
managing SCD in children and young adults.
There are many potential benefits to adapting the
Project ECHO model for improving evidence-based care
of SCD. Use of a low-cost technology for provider
education should be beneficial particularly for providers
who cannot attend conferences and meetings due to time
limitations and travel costs, and especially for PCPs
located in low-resource settings. Moreover, the model
allows providers to participate in the educational activity
in their own clinic setting, along with their local clinical
team, thereby increasing the likelihood of application.
Further, the Project ECHO model is designed to facilitate meaningful, interactive, continuous learning. The
model closely follows the framework of outcomes assessments in developing physician clinical skills. Utilizing the
NHLBI evidence-based guidelines as the didactic presentation curriculum, providers have a guide for what
declarative knowledge they should have when treating
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patients. Second, ‘knowing how’, or procedural knowledge,
may be further refined for providers who may not be
comfortable managing patients or prescribing hydroxyurea. Though the ‘community of practice’ and mentoring,
providers begin to build the procedural skills of how
to manage SCD by presenting cases, or participation in
case discussions. Finally, providers can demonstrate their
competency by implementing what they have learned
through STORM TeleECHO and perform more confidently and improve patient outcomes (39) while having
continuous feedback and mentoring from clinical experts.
Project ECHO’s educational foundation is based on
postgraduate medical education principles and grounded
in three key learning theories: social cognitive theory,
situated learning theory, and community of practice
theory (40). Social cognitive theory is the idea that
participants must believe there is a benefit in learning a
new behavior, develop confidence in performing this
behavior, and receive reinforcement of positive behavior
changes (41). Situated learning theory centers on the
concept of providing learners with modeled experiences to
engage their interest and simplify tasks while learning a
new skill (42). Community of practice theory focuses on
the significance of participating in a collaborative community with peers and content experts, on a continual
basis (43). A recent study of urban community health
center providers in Chicago, who participated in an ECHO
project to improve management of resistant hypertension,
showed that the ECHO model effectively combines these
key established learning theories to maximize educational
opportunity for participants (36). STORM TeleECHO
will build a community of practice for SCD in the
Midwest. Regional PCPs, who may have had limited
interactions with hematology specialists, will be able to
build strong relationships within the network that will be
beneficial for evidence-based care and co-management
throughout the lifespan of patients with SCD: from initial
diagnosis with newborn screening to the transition from
teen to young adult care, and even to managing severe
complications later in life.
This model for regional telementoring is not without
limitations. The STORM TeleECHO project may initially
reach only providers with a vested interest in caring for
patients with SCD. However, participation from all six
states in the STORM network may eventually broaden
the reach particularly since clinical experts from each
state will be presenting didactics and cases. Another
potential limitation is the concern about medicolegal
liability for both parties. It is important to note that the
Project ECHO methodology is not telemedicine, which is
to provide shared legal responsibility of clinical care for a
primary patient, but instead a telementoring approach
to connect, teach, and empower PCPs to become more
knowledgeable about how to deliver evidence-based care
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to their existing patients, and to increase their confidence
and capacity to expand their practice.
We have designed and replicated Project ECHO to
improve provider competence in managing children and
young adults with SCD. Through STORM TeleECHO,
we will disseminate the NHLBI evidence-based guidelines
with the goal of increasing equitable care and improving
clinical outcomes. This low-cost technology-enhanced
CME intervention has potential for replication in other
pediatric chronic illnesses populations facing health disparities including lack of access to high-quality evidencebased care. Planned program assessments guided by the
conceptual framework of an approach to continuous planning and assessment in CME will determine its utility
for improving uptake and care for children and adults
with SCD.
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